Tianjin Hubin Pangu Gene Science Development Co., Ltd., established on 2014-05-07, Business scope includes gene technology and biological product research and development,technology transfer,technical consulting,Technical Services;medical instruments,drug development,Technology Consulting and Transfer;Biological product(food,except medicines)Wholesale and retail;Engage in import and export business permitted by national laws and regulations;account Serive.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Yuhan Corp. engages in the manufacture of pharmaceutical, health foods, cosmetics and consumer products. It operates through the following business areas: Pharmaceutical, Household products and Active Pharmaceutical Ingredient (API). Its products include APIs and intermediates and finished products such as ethical drugs, over-the-counter drugs and others. Its services include custom development and manufacturing services and supply chain management. The company was founded by Il-Han New on June 20, 1926 and is headquartered Seoul, South Korea.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Jiangsu Academy of Agricultural Sciences is a Chinese private company located in Nanjing, with subsidiaries in China, that engages in agriculture research and development.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

Araxes Pharma LLC is an American private company located in La Jolla, CA. The firm develops drugs for the treatment of cancer and other diseases.

Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

Jacobio Pharmaceuticals, founded in 2015 in Beijing China, is a clinical-stage biotech company dedicated to the development of global truly innovative drugs for the unmet needs in China and abroad. The vision and mission of Jacobio have become a global leader to provide revolutionary therapies for serious and life-threatening diseases such as cancer, autoimmune and infectious diseases. Jacobio is founded by seasoned executives from top global and local pharmaceuticals companies who have an astounding track record of success and backed by prestigious venture capital firms such as Lilly Asia Ventures and Qiming Capitals. Dr. Yinxiang Wang, the co-founder and chairman of Jacobio, also is one of the founders of Betta Pharmaceuticals, an A-share listed innovative pharmaceutical company, and the national "The Recruitment Program of Global Experts". The most senior management team has over 20 years of drug R&D experience and successfully brought several innovative drugs into the clinical and market stage. Within 3 years, Jacobio has quickly established a compelling drug R&D team of over 100 employees and one-stop capability covering target discovery, med-chemistry, pharmacology, CMC formulation, clinical, and registration. With those, the company has built up a rich pipeline of 8-10 assets with clear competitive advantages and excellent drug properties. JAB-3068, the most advanced program for Jacobio, has focused on a novel target potential for both immunotherapy and target therapy and enter Phase I clinical trial in US and IND approved at China and clinical trials would be initiate at China very soon.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California in 1971, but conducted most of its operations in nearby Emeryville. Before merging with another company in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

AEterna Zentaris GmbH engages in biopharmaceutical research. It specializes in the fields of oncology and endocrinology. The company is headquartered in Frankfurt, Germany.

Scientic, Inc. provides systems engineering services. The firm specializes in scientific, engineering radiation survivability, test, prototyping and production. The company was founded in 2008 and is headquartered in Huntsville, AL.